ACADIA Pharmaceuticals Help Lift Biotech ETFs
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength…
SBIO
ALPS Medical Breakthroughs ETF
$33.50 +$0.49
(+1.48%)
As of 8:38:37 PM EDT | 10/17/19 | Market Closed
SBIO Trading Data
Open
$33.12
Low Price
$33.1
High Price
$33.54
Previous Last Price
$33.01
Bid Size
$ X
Ask Size
$ X
SBIO Portfolio Data
AUM
$163,550,000
Shares
5,000
PE Ratio
0
Price / Book Ratio
3.92
Expense Ratio
0.5
Net Asset Value
$32.71
Volume
Volume
46,000
Avg. Volume (YDT)
37,140
Dollar Volume
$661,725
Weekly Avg. Volume
30,280
Monthly Avg. Volume
36,040
Quarterly Avg. Volume
29,846
SBIO Fund Description
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
SBIO Chart
SBIO Summary
Fund Family
ALPS Holdings
Tracks This Index
ALPS Medical Breakthroughs ETF
Inception Date
2015-01-05
Asset Class
Portfolio-Multi Asset
Asset Class Size
Healthcare
SBIO Classification
Region (General)
Global
Region (Specific)
Sector
Health Care
Equity Index
Leveraged Family
SBIO Technicals
Alpha
1.86
Beta
1.6
Leverage
Long
Standard Deviation
2.21
SBIO Dividends
Dividend Date
2018-12-20
Latest Dividend
0.784
Annual Dividend
0.78
Annual Dividend Rate
0.78
Annual Dividend Yield
2.4
SBIO Performance
YTD Return
19.05%
1 Year Return
-8.12%
3 Year Return
41.65%
5 Year Return
0%
10 Year Return
32.89%
SBIO Related Articles
Biotech ETFs Jump: Keep an Eye on XBI, IBB & SBIO
Biotech ETFs are movin’ on up on news that Pfizer is buying Array BioPharma for over $10 billion. SPDR S&P Biotech…
Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal
Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY)…
3 Biotech Sector ETFs Bucked the Risk-Off Trend
While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats…
A Targeted ETF to Capture M&A, Consolidation in the Biotech Space
The biotechnology space is filled with new drug makers and treatments that help make lives better, and large pharma has…
Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook
Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after…
© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.